Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). (Q36381009)

13 August 2017

1 reference

title

Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). (English)

1 reference

13 August 2017

0 references

Renke Maas

1 reference

13 August 2017

publication date

1 July 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

10 Suppl 1

1 reference

13 August 2017

page(s)

S49-57

1 reference

The L-arginine-nitric oxide pathway

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Asymmetrical dimethylarginine: the Uber marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

A proteomic analysis of arginine-methylated protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

State of the arg: protein methylation at arginine comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

ADMA and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Dietary composition as a determinant of plasma asymmetric dimethylarginine in subjects with mild hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

The clinical pharmacology of L-arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM605OA

10.1191/1358863X05VM605OA

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference